05 September 2016
A new report by visiongain predicts that the world infusion pumps market will reach $8.54bn in 2016. This forecast and others appear in World Infusion Devices Market 2016-2026: Forecasts for Insulin Pumps, Enteral Feeding Pumps, other Infusion Pumps for Insulin Infusion, Drug Delivery, Oncology, Antibiotics, Analgesia, Hydration, Immune Globulin Intravenous, Chelation Therapy and Immune Globulin Subcutaneous Therapy, published in July 2016. Visiongain is a business information provider based in London, UK.
The world infusion pump market is on the rise. In 2016, the market was worth an estimated $8.54bn with steady growth projected for the next decade. The advent of modern technology has driven growth in this segment through innovation, while an increasing patient base and increasing healthcare expenditure in emerging markets counties to spur growth. In this report we assess the global infusion pumps market by nation, as well as the individual submarkets within it. Submarkets of interest include insulin pumps for the treatment of diabetes, chemotherapy pumps for oncology therapeutics, and eternal feeding pump to provide nutrition. An overview of the major global drug delivery market will also be provided, along with a ten year financial forecast. In addition, the report will analyse the leading products on the market, the infusion pump R&D pipeline, and the competitive landscape in order to provide a comprehensive overview of the forces at work within the world infusion pump industry.
“The infusion pump has revolutionized the trajectory of modern medicine. Throughout the forecast period this market will continue to develop; driven by an aging global population, a rise in chronic disease prevalence and a number of technological innovations. Ultimately changing the way we treat disease and manage patients in the coming decade.”
Arvind Deol, Pharmaceutical and Medical Device Industry Analyst, visiongain 2016
Included in the report is a lengthy discussion of the strengths and weakness of the field of infusion pumps, as well as the opportunities and threats facing developers. The report includes a forecast of the global infusion pumps market through to 2026, as well as forecasts for three submarkets:
• Insulin pumps,
• Enteral feeding pumps
• Other pumps (a grouped category inclusive of chemotherapy pumps and PCA infusion pumps)
National markets are also discussed, with forecasts to 2026 provided for the US, EU5 (Germany, UK, France, Italy and Spain), Japan, China, India, Brazil, Russia and South Korea.
This independent, 251-page report guarantees you will remain better informed than your competition. With 148 tables and figures examining the infusion pumps market space, the report gives you a visual, one-stop breakdown of your market. In addition, this report provides analysis of competing technologies, with forecasts to 2026 for the global drug delivery technologies market and the following submarkets:
• Oral drug delivery
• Inhalation drug delivery
• Injectable/implantable drug delivery
• Transdermal drug delivery
• Ocular drug delivery
• Nasal drug delivery
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.